Corcept Therapeutics (NASDAQ:CORT) Announces Earnings Results, Misses Estimates By $0.13 EPS

Corcept Therapeutics (NASDAQ:CORT) announced its quarterly earnings data on Tuesday. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.13), FiscalAI reports. The business had revenue of $202.13 million for the quarter, compared to analysts’ expectations of $254.94 million. Corcept Therapeutics had a net margin of 14.19% and a return on equity of 15.99%. The firm’s revenue was up 11.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.26 EPS.

Here are the key takeaways from Corcept Therapeutics’ conference call:

• Corcept reported 2025 revenue of $761 million (up from $675M) and provided 2026 revenue guidance of $900 million–$1 billion, driven primarily by its Cushing’s syndrome business.
• The FDA issued a complete response letter denying approval of relacorilant for Cushing’s syndrome; the company plans an April meeting with FDA and intends to appeal, resubmit, or possibly run a new study — creating regulatory uncertainty and potential delays.
• The Phase 3 ROSELLA trial in platinum‑resistant ovarian cancer met both primary endpoints, showing a 35% reduction in risk of death (HR 0.65, p=0.0004) and a 4.1‑month median OS benefit; Corcept expects an oncology PDUFA date of July 11 and foresees rapid adoption if approved.
• Demand for Korlym surged in 2025 (37% more tablets; record new prescriptions and prescribers); prior specialty pharmacy capacity issues are being resolved after a vendor transition, and management expects continued commercial growth (targeting at least $2 billion annual Cushing revenue by decade end).
• The pipeline advanced: a Phase 2b MASH study (MONARCH) is fully enrolled with results due by year‑end, and ALS data (DASLES) showed an 84% reduction in risk of death (p=0.0009), prompting a planned pivotal trial after addressing GI tolerability via dose‑titration work.

Corcept Therapeutics Stock Up 3.2%

Shares of NASDAQ:CORT opened at $36.48 on Wednesday. The business has a 50-day moving average price of $47.21 and a 200 day moving average price of $66.45. The company has a current ratio of 3.14, a quick ratio of 3.07 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $3.84 billion, a price-to-earnings ratio of 41.46 and a beta of 0.25. Corcept Therapeutics has a 12-month low of $28.66 and a 12-month high of $117.33.

Insider Activity at Corcept Therapeutics

In related news, insider William Guyer sold 20,000 shares of the stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $40.87, for a total transaction of $817,400.00. Following the completion of the transaction, the insider owned 1,235 shares of the company’s stock, valued at approximately $50,474.45. This trade represents a 94.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Joseph Douglas Lyon sold 5,000 shares of Corcept Therapeutics stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $79.53, for a total transaction of $397,650.00. Following the completion of the sale, the insider owned 10,277 shares of the company’s stock, valued at $817,329.81. This trade represents a 32.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 125,000 shares of company stock worth $8,301,450. 20.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Corcept Therapeutics

A number of institutional investors have recently modified their holdings of CORT. AQR Capital Management LLC boosted its holdings in Corcept Therapeutics by 546.9% during the 3rd quarter. AQR Capital Management LLC now owns 1,507,209 shares of the biotechnology company’s stock valued at $125,264,000 after acquiring an additional 1,274,215 shares during the period. UBS Group AG lifted its position in shares of Corcept Therapeutics by 413.8% during the third quarter. UBS Group AG now owns 549,938 shares of the biotechnology company’s stock worth $45,705,000 after purchasing an additional 442,898 shares in the last quarter. Morgan Stanley boosted its stake in shares of Corcept Therapeutics by 34.1% in the fourth quarter. Morgan Stanley now owns 1,592,059 shares of the biotechnology company’s stock valued at $55,404,000 after purchasing an additional 405,081 shares during the period. HRT Financial LP acquired a new position in shares of Corcept Therapeutics in the second quarter valued at approximately $14,753,000. Finally, Tang Capital Management LLC acquired a new position in shares of Corcept Therapeutics in the fourth quarter valued at approximately $5,455,000. 93.61% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on CORT shares. HC Wainwright dropped their price target on Corcept Therapeutics from $105.00 to $67.00 and set a “buy” rating for the company in a research report on Friday, February 20th. Truist Financial set a $50.00 price objective on Corcept Therapeutics in a research note on Wednesday, December 31st. Canaccord Genuity Group raised their target price on Corcept Therapeutics from $99.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, January 23rd. Weiss Ratings reiterated a “hold (c)” rating on shares of Corcept Therapeutics in a report on Monday, December 29th. Finally, Zacks Research lowered shares of Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 13th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $77.17.

Trending Headlines about Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Company set 2026 revenue guidance of $900M–$1.0B and reiterated the near‑term potential of relacorilant in oncology, a development investors view as a material growth driver that could justify valuation upside if approval and launches proceed as expected. Corcept outlines $900M–$1B 2026 revenue guidance as relacorilant oncology approval nears
• Positive Sentiment: Company released audited Q4 and full‑year 2025 results and issued an optimistic corporate update, highlighting progress on commercial execution and pipeline milestones that some investors are treating as evidence management can deliver on the guidance. Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update
• Neutral Sentiment: Management’s Q4 earnings call and transcript provide detail on revenue drivers, relacorilant regulatory interactions and R&D priorities; useful for investors assessing timing and probability of approval but containing no immediate new catalyst. Corcept Therapeutics Incorporated (CORT) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Q4 results missed Street estimates: EPS of $0.20 (vs. consensus ~ $0.33) and revenue of $202.1M (vs. ~$255M), though revenue was up ~11% year‑over‑year — the miss and lower near‑term visibility prompted some analysts and headlines to flag weaker than expected performance. Corcept Therapeutics (CORT) Q4 Earnings and Revenues Miss Estimates
• Negative Sentiment: Multiple law firms and plaintiff announcements: several securities‑class action filings and investor notices allege the company failed to disclose FDA concerns about relacorilant’s NDA; the legal overhang (and references to a prior ~50% stock decline tied to “evidence gaps”) increases litigation risk and near‑term uncertainty. CORT Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Corcept Therapeutics Inc.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.